← Leaderboards
David T Fung
New York/R&D/Ctr/Translational Med/Ther
$3,307,169
Attributed
$5,128,488
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,128,488 · 3
By mechanism
R44$5,128,488 · 3
Top collaborators
- Li Sun6 shared
Most similar at New York/R&D/Ctr/Translational Med/Ther
Same institution · by research overlap
- Daniel J Leong$347,193
Others in their field
Other Emerging Leaders on “Commercialization”
- Joel A Lipkin · Four Points Technology, Llc$185,041,546
- Terry Drinkwine · Carahsoft Technology Corporation$94,287,243
- John E West · University Of Texas At Austin$94,000,000
- Mark Marino · Venturewell$64,226,669
- Martha Hering · Westat, Inc.$57,098,843
- Julie Brisset · The University Of Central Florida Board Of Trustees$41,275,036
Research focus
CommercializationResearch And DevelopmentTendon StructureDeteriorationAdverse EffectsImpairmentSwellingTendon RuptureTherapeutic EffectEffective TherapyPainPerformancePathologyTendinopathyChronicPain BehaviorAnimal ModelEfficacy TestingOryctolagus CuniculusDoseExosomeFda ApprovedMechanical PropertiesBusinesses
Grant awards (8)
Exosome drug for tendinopathy$719,580
R44 · FY2025 · AG · contact PI
Exosome drug for tendinopathy$766,269
R44 · FY2024 · AG · contact PI
miRNA drug for tendinopathy$560,060
R44 · FY2024 · AG · contact PI
miRNA drug for tendinopathy$568,966
R44 · FY2023 · AG · contact PI
miRNA drug for tendinopathy$737,376
R44 · FY2022 · AG · contact PI
A novel product for tendinopathy treatment$831,571
R44 · FY2021 · AG
A novel product for tendinopathy treatment$20,300
R44 · FY2021 · AG
A novel product for tendinopathy treatment$924,366
R44 · FY2020 · AG